Fig. 3.

Overview of the treatment period of the BM32 trial. (a) Subjects received seven injections of placebo or BM32 over two years as depicted in the time line. Visits during which blood samples were obtained are indicated. (b) IgG responses of subjects vaccinated with BM32 or placebo towards preS and synthetic preS-derived overlapping peptides. Shown are optical density values (y-axes: OD values, means of triplicate determination) corresponding to IgG levels towards preS and peptides P1–P8 measured in subjects with (red symbols) or without (black symbols) prior HBV vaccination who had been immunized with BM32 or placebo before (V5) and at different time points after immunization (V8 and V15) (x-axes). Medians (horizontal bars) and significant differences are indicated: *P < 0.05, **P < 0.01, ***P < 0.001.